SecBot SecBot
SECBOTREPLAY Home › Report › ACRV

ACRV · S-3 shelf $300M filed

Acrivon Therapeutics, Inc. · S-3 filed Nov 16, 2026 at 17:11 ET

At the news

NEUTRALIMPACT 3/10

S-3 filed Nov 16, 2026 at 17:11 ET

Acrivon Therapeutics filed a new S-3 shelf registration statement for up to $300 million in securities (common stock, preferred stock, debt securities, warrants, units), replacing a prior shelf with $292.7 million of unsold securities carried forward. The filing comes on the same day as Q3 2026 results showing $77.8 million in cash, expected to fund operations into Q4 2027, and no immediate pricing or offering was announced. The shelf provides broad financing flexibility for a clinical-stage biotech with no revenue and ongoing losses.

  • S-3 shelf registration filed for up to $300,000,000 in aggregate securities
  • $292,701,082.80 of unsold securities carried forward from prior S-3 (File No. 333-275854)
  • $7,298,917.20 of newly registered securities; registration fee of $635.01
  • Filed on same day as Q3 2026 earnings release and 10-Q

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access